P Goggin1, C Sauvageau1,2, V Gilca1,2, F Defay1, G Lambert1, S Mathieu-C1,3, J Guenoun4, E Comète4, F Coutlée4,5. 1. a Direction des Risques Biologiques et de La Santé au Travail, Institut National de Santé Publique du Québec , Montréal and Québec , Québec , Canada. 2. b Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec , Québec , Canada. 3. c Département de Psychopédagogie et D'andragogi, Faculté des Sciences de L'éducation , Université de Montréal , Montréal , Québec , Canada. 4. d Département de Microbiologie et Infectiologie , Centre hospitalier de l'Université de Montréal , Montréal , Québec , Canada. 5. e Département de Microbiologie et Immunologie , Université de Montréal , Montréal , Québec , Canada.
Abstract
BACKGROUND: In Quebec, Canada, a school-based HPV vaccination for girls has been offered since 2008. The vaccine used in the program targets HPV16/18, responsible for ∼70% of cervical cancers and HPV6/11, responsible for the majority of anogenital warts. The objective of this study was to assess the prevalence of HPV in vaccinated and unvaccinated women. METHODS: Women aged 17-29 years were eligible to participate. Participants' age, vaccination status and diverse risk factors were assessed by a computer-assisted questionnaire. Biological specimens were obtained by self-sampling. HPV genotyping was performed by Linear Array. RESULTS: A total of 2,118 women were recruited. 2,042 completed the questionnaire and 1,937 provided a vaginal sample. Vaccination coverage varied from 83.5% in women aged 17-19 to 19.1% in those aged 23-29. The overall prevalence of HPV in sexually active women was 39.4% (95%CI: 37.0-41.7) and 56.7% of infected women had multiple type infections. The prevalence of vaccine HPV types varied by age and vaccination status except for women aged 23-29 for whom similar results were observed. Vaccine HPV types were detected in 0.3%, 1.4% and 10.5% of vaccinated women aged 17-19, 20-23, and 23-29 (p<0.05), respectively. HPV16 or HPV18 were detected in 10 women having received at least one dose of vaccine. Nine of these women were already sexually active at the time of vaccination. CONCLUSION: Infections with HPV types included in the vaccine are rare in women aged less than 23 years and are virtually absent in those who received at least one dose of vaccine before sexual debut.
BACKGROUND: In Quebec, Canada, a school-based HPV vaccination for girls has been offered since 2008. The vaccine used in the program targets HPV16/18, responsible for ∼70% of cervical cancers and HPV6/11, responsible for the majority of anogenital warts. The objective of this study was to assess the prevalence of HPV in vaccinated and unvaccinated women. METHODS:Women aged 17-29 years were eligible to participate. Participants' age, vaccination status and diverse risk factors were assessed by a computer-assisted questionnaire. Biological specimens were obtained by self-sampling. HPV genotyping was performed by Linear Array. RESULTS: A total of 2,118 women were recruited. 2,042 completed the questionnaire and 1,937 provided a vaginal sample. Vaccination coverage varied from 83.5% in women aged 17-19 to 19.1% in those aged 23-29. The overall prevalence of HPV in sexually active women was 39.4% (95%CI: 37.0-41.7) and 56.7% of infected women had multiple type infections. The prevalence of vaccine HPV types varied by age and vaccination status except for women aged 23-29 for whom similar results were observed. Vaccine HPV types were detected in 0.3%, 1.4% and 10.5% of vaccinated women aged 17-19, 20-23, and 23-29 (p<0.05), respectively. HPV16 or HPV18 were detected in 10 women having received at least one dose of vaccine. Nine of these women were already sexually active at the time of vaccination. CONCLUSION: Infections with HPV types included in the vaccine are rare in women aged less than 23 years and are virtually absent in those who received at least one dose of vaccine before sexual debut.
Entities:
Keywords:
HPV prevalence; HPV vaccine; Human papillomavirus; self-sampling
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Eric P F Chow; Jennifer A Danielewski; Glenda Fehler; Sepehr N Tabrizi; Matthew G Law; Catriona S Bradshaw; Suzanne M Garland; Marcus Y Chen; Christopher K Fairley Journal: Lancet Infect Dis Date: 2015-07-19 Impact factor: 25.071
Authors: Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-06 Impact factor: 4.254
Authors: R Karlsson; M Jonsson; K Edlund; M Evander; A Gustavsson; E Bodén; E Rylander; G Wadell Journal: Sex Transm Dis Date: 1995 Mar-Apr Impact factor: 2.830
Authors: Sepehr N Tabrizi; Julia M L Brotherton; John M Kaldor; S Rachel Skinner; Bette Liu; Deborah Bateson; Kathleen McNamee; Maria Garefalakis; Samuel Phillips; Eleanor Cummins; Michael Malloy; Suzanne M Garland Journal: Lancet Infect Dis Date: 2014-08-05 Impact factor: 25.071
Authors: Charlotte H Lenselink; Willem J G Melchers; Wim G V Quint; Annelies M J Hoebers; Jan C M Hendriks; Leon F A G Massuger; Ruud L M Bekkers Journal: PLoS One Date: 2008-11-17 Impact factor: 3.240
Authors: Madhura S Rane; Libby C Page; Emma McVeigh; Kaetlin Miller; David Baure; M Elizabeth Halloran; Jeffrey S Duchin Journal: Vaccine Date: 2021-02-25 Impact factor: 3.641
Authors: Newton Sergio de Carvalho; Roberto José de Carvalho da Silva; Isabel Cristina do Val; Maria Luiza Bazzo; Mariângela Freitas da Silveira Journal: Rev Soc Bras Med Trop Date: 2021-05-17 Impact factor: 1.581
Authors: Emilien Jeannot; Manuella Viviano; Charlotte de Pree; Mona Amadane; Emmanuel Kabengele; Pierre Vassilakos; Patrick Petignat Journal: Int J Environ Res Public Health Date: 2018-07-09 Impact factor: 3.390